Literature DB >> 26677446

Myasthenia gravis and thymic neoplasms: A brief review.

Ritesh Kumar1.   

Abstract

Thymoma is the most common mediastinal tumor. They have varied presentation ranging from asymptomatic incidental mediastinal masses to locally extensive tumor with compressive symptoms and distant metastases. They have frequent association with various paraneoplastic syndromes (PNS). The most common PNS associated with thymoma is myasthenia gravis (MG). Patients of thymoma with MG have a favourable outcome due to early disclosure of the disease. Histologically they are classified into five subtypes and Masaoka-Koga staging system is used for staging. Surgery, chemotherapy and radiotherapy play an important role along with anti-myasthenia drugs. This review would like to highlight the association of thymoma with MG and associated clinical and therapeutic issues.

Entities:  

Keywords:  Chemotherapy; Myasthenia gravis; Radiotherapy; Surgery; Thymoma

Year:  2015        PMID: 26677446      PMCID: PMC4677085          DOI: 10.12998/wjcc.v3.i12.980

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  27 in total

Review 1.  Thymoma classification: current status and future trends.

Authors:  Saul Suster; Cesar A Moran
Journal:  Am J Clin Pathol       Date:  2006-04       Impact factor: 2.493

Review 2.  Paraneoplastic neurological degenerations: keys to tumour immunity.

Authors:  Matthew L Albert; Robert B Darnell
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

Review 3.  Standard outcome measures for thymic malignancies.

Authors:  James Huang; Frank C Detterbeck; Zuoheng Wang; Patrick J Loehrer
Journal:  J Thorac Oncol       Date:  2010-12       Impact factor: 15.609

4.  Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

Authors:  G Giaccone; A Ardizzoni; A Kirkpatrick; M Clerico; T Sahmoud; N van Zandwijk
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

5.  Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.

Authors:  P J Loehrer; M Jiroutek; S Aisner; J Aisner; M Green; C R Thomas; R Livingston; D H Johnson
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

Review 6.  Acetylcholine receptors and myasthenia.

Authors:  J M Lindstrom
Journal:  Muscle Nerve       Date:  2000-04       Impact factor: 3.217

7.  Chemotherapy of invasive thymoma.

Authors:  A Fornasiero; O Daniele; C Ghiotto; F Sartori; F Rea; M Piazza; L Fiore-Donati; P Morandi; S M Aversa; A Paccagnella
Journal:  J Clin Oncol       Date:  1990-08       Impact factor: 44.544

8.  Results from surgical treatment for thymoma. 43 years of experience.

Authors:  T Murakawa; J Nakajima; T Kohno; M Tanaka; J Matsumoto; E Takeuchi; S Takamoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-02

Review 9.  Natural history and treatment of malignant thymoma.

Authors:  D Cowen; J M Hannoun-Levi; M Resbeut; C Alzieu
Journal:  Oncology (Williston Park)       Date:  1998-07       Impact factor: 2.990

Review 10.  Treatment of autoimmune myasthenia gravis.

Authors:  David P Richman; Mark A Agius
Journal:  Neurology       Date:  2003-12-23       Impact factor: 9.910

View more
  4 in total

Review 1.  Thymectomy in Myasthenia Gravis.

Authors:  Yener Aydin; Ali Bilal Ulas; Vahit Mutlu; Abdurrahim Colak; Atilla Eroglu
Journal:  Eurasian J Med       Date:  2017-02

2.  A case of uniportal VATS thymectomy for Thymoma associated with myasthenia gravis and toxic multinodular goiter.

Authors:  Osama N Dukmak; Ruba Dweik; Nadeen Hashlamoun; Rahaf Qawasmeh; Mohammad Eid Al Mohtasib; Yousef Abu Asbeh
Journal:  Int J Surg Case Rep       Date:  2022-05-11

3.  Risk of malignancies in patients with inflammatory bowel disease who used thiopurines as compared with other indications: a territory-wide study.

Authors:  Kelvin Y C Zheng; Chuan-Guo Guo; Irene O L Wong; Lijia Chen; Ho Yin Chung; Ka Shing Cheung; Wai K Leung
Journal:  Therap Adv Gastroenterol       Date:  2020-11-18       Impact factor: 4.409

4.  Myasthenia gravis as a prognostic marker in patients with thymoma.

Authors:  Bernardo Cacho-Díaz; Karen Salmerón-Moreno; Nydia A Lorenzana-Mendoza; Julia Texcocano; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.